Related Experiment Video
Updated: Jul 14, 2026
06:21
Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity
Ravibhushan Singh1, Jeff L Browning, Ralph Abi-Habib
1Cancer Research Institute, Scott & White Memorial Hospital, 5701 South Airport Road, Temple, TX 76502, USA.
Anti-Cancer Drugs
|June 22, 2007
Summary
Engineered proaerolysin specifically targets prostate-specific antigen (PSA). This modified bacterial protoxin shows potential for targeted prostate cancer therapy by selectively activating in the presence of PSA.
Area of Science:
- Biochemistry
- Molecular Biology
- Toxicology
Background:
- Proaerolysin is a bacterial protoxin activated by proteases like furin.
- Targeted activation mechanisms are crucial for developing selective therapeutic agents.
Purpose of the Study:
- To engineer proaerolysin for prostate-specific antigen (PSA) sensitivity.
- To evaluate the efficacy and specificity of the modified protoxin for prostate conditions.
Main Methods:
- Genetic engineering of proaerolysin to replace the furin-cleavage site with a PSA-selective sequence.
- Expression and purification of recombinant modified proaerolysin from Aeromonas salmonicida.
- Assessing protoxin sensitivity to PSA and furin in vitro and in human cell lines.
Main Results:
- Recombinant modified proaerolysin demonstrated no furin sensitivity and enhanced PSA sensitivity.
- Prostate cancer cells showed significantly increased sensitivity to the modified protoxin in the presence of active PSA.
- Normal human cells, except for prostate and renal epithelial cells, exhibited low sensitivity.
Conclusions:
- Engineered proaerolysin is a potent PSA-sensitive protoxin.
- This modified protoxin holds promise for the regional therapy of prostate growths, both benign and malignant.
